5 completed, 4 recruiting, 1 unknown, 1 withdrawn. 6 Phase 2, 4 Phase 3, 3 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Recruiting 1, Unknown 1 |
| Phase 3 | 4 | Completed 1, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 4 | 3 | Recruiting 2, Completed 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Semaglutide Injectable Product: new trials by email Literature Review of Semaglutide Injectable Product trials Research Report on Semaglutide Injectable Product
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity Semaglutide Injectable Product, Placebo - Major Depressive Disorder | Phase 4 | Recruiting | Nordsjaellands Hospital | 116 | 2025-09-11 | 2026-02-06 |
| Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes Semaglutide Injectable Product, Placebo - Spinal Cord Injuries, Type 2 Diabetes | Phase 4 | Recruiting | Marzieh Salehi | 50 | 2025-04-11 | 2026-10-05 |
| Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS) Metformin, Semaglutide Injectable Product - Polycystic Ovary Syndrome | Phase 2 / Phase 3 | Unknown | University of Hull | 60 | 2025-03-01 | 2024-05-10 |
| A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist NG101, Placebo, Semaglutide Injectable Product - Overweight and Obesity, Healthy | Phase 2 | Completed | Neurogastrx, Inc. | 120 | 2024-06-24 | 2025-09-04 |
| Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure Semaglutide Injectable Product, Calorie-restricted diet - Heart Failure With Reduced Ejection Fraction, Obesity | Phase 2 / Phase 3 | Recruiting | Jens D Hove, MD,PHD | 100 | 2024-04-30 | 2026-06-23 |
| Semaglutide in CFRD Semaglutide - Cystic Fibrosis, Cystic Fibrosis-related Diabetes | Phase 2 / Phase 3 | Completed | University of Minnesota | 8 | 2023-10-16 | 2026-01-21 |
| Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity? Semaglutide Injectable Product, Placebo - Alcohol Abuse, Alcohol Addiction | Phase 2 | Completed | Psychiatric Centre Rigshospitalet | 108 | 2023-06-13 | 2025-08-05 |
| Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults Semaglutide Injectable Product, Lifestyle Counseling - Aging, Diabetes Mellitus, Type 2 | Phase 4 | Completed | The University of Texas Health Science Center at San Antonio | 20 | 2023-04-01 | 2025-05-04 |
| Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients Semaglutide Injectable Product, Placebo - Atrial Fibrillation, Overweight and Obesity | Phase 3 | Withdrawn | Axel Brandes | 2022-10-01 | 2023-11-03 | |
| Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV Semaglutide Injectable Product, Standard of care - Obesity, HIV-1-infection | Not applicable | Recruiting | University College Dublin | 80 | 2022-06-22 | 2026-04-29 |
| Effects of Semaglutide in HIV-Associated Lipohypertrophy Semaglutide Injectable Product, Placebo - HIV/AIDS, Lipohypertrophy | Phase 2 | Completed | Case Western Reserve University | 108 | 2019-05-16 | 2026-10-27 |
Obesity (6) · Overweight (3) · Diabetes Mellitus, Type 2 (2) · Weight Loss (2) · Acquired Immunodeficiency Syndrome (1) · Alcoholism (1) · Atrial Fibrillation (1) · Cystic Fibrosis (1) · Depression (1) · Depressive Disorder, Major (1) · Polycystic Ovary Syndrome (1) · Prediabetic State (1) · Spinal Cord Injuries (1)
Axel Brandes (1) · Case Western Reserve University (1) · Jens D Hove, MD,PHD (1) · Marzieh Salehi (1) · Neurogastrx, Inc. (1) · Nordsjaellands Hospital (1) · Psychiatric Centre Rigshospitalet (1) · The University of Texas Health Science Center at San Antonio (1) · University College Dublin (1) · University of Hull (1) · University of Minnesota (1)
United States (5) · Denmark (3) · Ireland (1) · United Kingdom (1)
Allison R Eckard, MD (1) · Amir Moheet, MBBS (1) · Anders Fink-Jensen, MD, DMSc (1) · Axel Brandes, MD, DMSc (1) · Grace A McComsey, MD (1) · Jens D Hove (1) · Maj Vinberg, MD, PhD, DMSc (1) · Marzieh Salehi, MD (1) · Morten L Hansen, MD, PhD (1) · Thozhukat Sathyapalan, MD, FRCP (1) · Tiffany M Cortes, MD (1)
PMID 35039057, PMID 38964353, PMID 39269759, PMID 39779270, PMID 40123107, PMID 40160348, PMID 41098140, PMID 42070571, PMID 42752515, PMID 42921178
2023 (1), P30AG044271 (1), R01DK121619 (1), R01DK140144 (1)